European Foundation for the Study of Chronic Liver Failure (EF Clif), 08021 Barcelona, Spain.
Biochemistry and Molecular Genetics Service, Hospital Clínic-IDIBAPS-CIBERehd, 08036 Barcelona, Spain.
Sci Transl Med. 2020 Oct 21;12(566). doi: 10.1126/scitranslmed.aax5135.
Human serum albumin (HSA) is an emerging treatment for preventing excessive systemic inflammation and organ failure(s) in patients with acutely decompensated (AD) cirrhosis. Here, we investigated the molecular mechanisms underlying the immunomodulatory properties of HSA. Administration of HSA to patients with AD cirrhosis with elevated circulating bacterial DNA rich in unmethylated cytosine-phosphate-guanine dideoxynucleotide motifs (CpG-DNA) was associated with reduced plasma cytokine concentrations. In isolated leukocytes, HSA abolished CpG-DNA-induced cytokine expression and release independently of its oncotic and scavenging properties. Similar anti-inflammatory effects were observed with recombinant human albumin. HSA exerted widespread changes on the immune cell transcriptome, specifically in genes related to cytokines and type I interferon responses. Our data revealed that HSA was taken up by leukocytes and internalized in vesicles positively stained with early endosome antigen 1 and colocalized with CpG-DNA in endosomes, where the latter binds to Toll-like receptor 9 (TLR9), its cognate receptor. Furthermore, HSA also inhibited polyinosinic:polycytidylic acid- and lipopolysaccharide-induced interferon regulatory factor 3 phosphorylation and TIR domain-containing adapter-inducing interferon-β-mediated responses, which are exclusive of endosomal TLR3 and TLR4 signaling, respectively. The immunomodulatory actions of HSA did not compromise leukocyte defensive mechanisms such as phagocytosis, efferocytosis, and intracellular reactive oxygen species production. The in vitro immunomodulatory effects of HSA were confirmed in vivo in analbuminemic humanized neonatal Fc receptor transgenic mice. These findings indicate that HSA internalizes in immune cells and modulates their responses through interaction with endosomal TLR signaling, thus providing a mechanism for the benefits of HSA infusions in patients with cirrhosis.
人血清白蛋白(HSA)是一种新兴的治疗方法,可预防急性失代偿性(AD)肝硬化患者过度的全身炎症和器官衰竭。在这里,我们研究了 HSA 免疫调节特性的分子机制。给 AD 肝硬化患者输注富含未甲基化胞嘧啶-磷酸-鸟嘌呤二脱氧核苷酸基序(CpG-DNA)的循环细菌 DNA 可降低血浆细胞因子浓度。在分离的白细胞中,HSA 可独立于其膨胀和清除特性消除 CpG-DNA 诱导的细胞因子表达和释放。重组人白蛋白也观察到类似的抗炎作用。HSA 对免疫细胞转录组产生广泛的变化,特别是与细胞因子和 I 型干扰素反应相关的基因。我们的数据表明,HSA 被白细胞摄取,并在内吞小体中内化,这些内吞小体被早期内体抗原 1 阳性染色,并与内体中的 CpG-DNA 共定位,后者与 Toll 样受体 9(TLR9)及其同源受体结合。此外,HSA 还抑制多聚肌苷酸:多聚胞苷酸和脂多糖诱导的干扰素调节因子 3 磷酸化和 TIR 结构域包含的衔接子诱导的干扰素-β介导的反应,这分别是内体 TLR3 和 TLR4 信号的特有作用。HSA 的免疫调节作用不会损害白细胞防御机制,如吞噬作用、胞吐作用和细胞内活性氧物质的产生。在缺乏白蛋白的人源化新生 Fc 受体转基因小鼠中体内证实了 HSA 的体外免疫调节作用。这些发现表明,HSA 在内皮细胞中内化,并通过与内体 TLR 信号相互作用调节其反应,从而为肝硬化患者输注 HSA 的益处提供了一种机制。